tiprankstipranks
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Hong Kong Market
2269
Wuxi Biologics (Cayman)
RESEARCH TOOLSreports
Want to see HK:2269 full AI Analyst Report?

Wuxi Biologics (Cayman) (2269) Ratios

55 Followers

Wuxi Biologics (Cayman) Ratios

HK:2269's free cash flow for Q4 2025 was ¥0.49. For the 2025 fiscal year, HK:2269's free cash flow was decreased by ¥ and operating cash flow was ¥0.33. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 3.14 3.14 2.73 2.78 1.98
Quick Ratio
 2.97 2.97 2.56 2.54 1.74
Cash Ratio
 1.11 1.11 0.96 1.27 0.69
Solvency Ratio
 0.61 0.61 0.42 0.36 0.39
Operating Cash Flow Ratio
 0.77 0.77 0.61 0.61 0.59
Short-Term Operating Cash Flow Coverage
 5.10 5.09 2.14 8.10 4.19
Net Current Asset Value
¥ 15.47B¥ 15.47B¥ 12.07B¥ 8.64B¥ 5.12B
Leverage Ratios
Debt-to-Assets Ratio
 0.05 0.05 0.09 0.08 0.09
Debt-to-Equity Ratio
 0.07 0.07 0.12 0.11 0.13
Debt-to-Capital Ratio
 0.06 0.06 0.11 0.10 0.11
Long-Term Debt-to-Capital Ratio
 <0.01 <0.01 <0.01 0.04 0.04
Financial Leverage Ratio
 1.35 1.35 1.36 1.40 1.41
Debt Service Coverage Ratio
 5.07 4.79 2.14 6.67 3.91
Interest Coverage Ratio
 112.45 46.46 31.56 28.08 67.44
Debt to Market Cap
 0.01 0.01 0.04 0.02 0.01
Interest Debt Per Share
 0.80 0.81 1.25 1.13 1.08
Net Debt to EBITDA
 -0.75 -0.75 -0.52 -0.93 -0.32
Profitability Margins
Gross Profit Margin
45.95%45.98%40.97%40.08%44.04%
EBIT Margin
30.48%30.50%26.73%25.43%35.51%
EBITDA Margin
37.87%38.49%34.43%32.30%40.76%
Operating Profit Margin
30.48%30.50%26.63%26.12%28.44%
Pretax Profit Margin
33.30%33.30%25.89%24.50%35.09%
Net Profit Margin
22.53%22.53%17.97%19.96%28.95%
Continuous Operations Profit Margin
26.32%26.31%21.13%20.96%29.80%
Net Income Per EBT
67.66%67.64%69.42%81.45%82.50%
EBT Per EBIT
109.27%109.18%97.20%93.79%123.40%
Return on Assets (ROA)
7.64%7.50%5.89%6.01%8.92%
Return on Equity (ROE)
10.55%10.12%8.03%8.43%12.61%
Return on Capital Employed (ROCE)
11.88%11.68%10.29%9.09%10.79%
Return on Invested Capital (ROIC)
9.18%9.03%7.96%7.66%8.84%
Return on Tangible Assets
7.88%7.75%6.10%6.23%9.31%
Earnings Yield
4.31%4.20%4.99%3.14%2.00%
Efficiency Ratios
Receivables Turnover
 2.43 2.39 3.23 2.73 2.96
Payables Turnover
 10.69 10.50 14.76 12.25 10.76
Inventory Turnover
 8.10 7.96 7.25 5.78 3.75
Fixed Asset Turnover
 0.73 0.71 0.66 0.57 0.59
Asset Turnover
 0.34 0.33 0.33 0.30 0.31
Working Capital Turnover Ratio
 1.28 1.30 1.31 1.50 1.50
Cash Conversion Cycle
 161.34 164.13 138.74 167.23 186.81
Days of Sales Outstanding
 150.44 153.03 113.10 133.88 123.31
Days of Inventory Outstanding
 45.06 45.86 50.38 63.15 97.43
Days of Payables Outstanding
 34.15 34.76 24.74 29.80 33.93
Operating Cycle
 195.50 198.89 163.48 197.03 220.75
Cash Flow Ratios
Operating Cash Flow Per Share
 1.61 1.59 1.28 1.12 1.33
Free Cash Flow Per Share
 0.68 0.69 0.32 0.11 -0.08
CapEx Per Share
 0.93 0.89 0.96 1.02 1.41
Free Cash Flow to Operating Cash Flow
 0.42 0.44 0.25 0.09 -0.06
Dividend Paid and CapEx Coverage Ratio
 1.73 1.78 1.33 1.10 0.94
Capital Expenditure Coverage Ratio
 1.73 1.78 1.33 1.10 0.94
Operating Cash Flow Coverage Ratio
 2.06 2.06 1.06 1.02 1.25
Operating Cash Flow to Sales Ratio
 0.30 0.30 0.28 0.27 0.36
Free Cash Flow Yield
2.30%2.46%1.91%0.40%-0.15%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 23.19 23.79 20.06 31.85 49.89
Price-to-Sales (P/S) Ratio
 5.43 5.36 3.60 6.36 14.44
Price-to-Book (P/B) Ratio
 2.39 2.41 1.61 2.68 6.29
Price-to-Free Cash Flow (P/FCF) Ratio
 43.47 40.64 52.28 247.65 -674.95
Price-to-Operating Cash Flow Ratio
 17.62 17.80 12.90 23.20 39.79
Price-to-Earnings Growth (PEG) Ratio
 0.47 0.53 0.00 -1.41 1.62
Price-to-Fair Value
 2.39 2.41 1.61 2.68 6.29
Enterprise Value Multiple
 13.59 13.17 9.95 18.75 35.12
Enterprise Value
 111.11B 107.62B 63.98B 103.16B 218.55B
EV to EBITDA
 13.59 13.17 9.95 18.75 35.12
EV to Sales
 5.15 5.07 3.43 6.06 14.31
EV to Free Cash Flow
 41.20 38.45 49.69 235.97 -668.91
EV to Operating Cash Flow
 17.35 16.85 12.26 22.10 39.44
Tangible Book Value Per Share
 12.83 12.68 10.66 10.08 8.18
Shareholders’ Equity Per Share
 11.88 11.74 10.24 9.69 8.40
Tax and Other Ratios
Effective Tax Rate
 0.21 0.21 0.18 0.14 0.15
Revenue Per Share
 5.43 5.27 4.57 4.09 3.66
Net Income Per Share
 1.22 1.19 0.82 0.82 1.06
Tax Burden
 0.68 0.68 0.69 0.81 0.83
Interest Burden
 1.09 1.09 0.97 0.96 0.99
Research & Development to Revenue
 0.04 0.04 0.04 0.05 0.04
SG&A to Revenue
 0.12 0.12 0.11 0.09 0.08
Stock-Based Compensation to Revenue
 0.02 0.00 0.07 0.07 0.08
Income Quality
 1.32 1.34 1.08 1.37 1.25
Currency in CNY